Emyria Limited (ASX:EMD)

Market Cap	28.13M
Revenue (ttm)	1.77M
Net Income (ttm)	-1.63M
Shares Out	611.45M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,640,658
Average Volume	4,401,109
Open	0.0490
Previous Close	0.0490
Day's Range	0.0440 - 0.0500
52-Week Range	0.0210 - 0.0510
Beta	0.58
RSI	70.57
Earnings Date	Aug 29, 2025

About Splunk

Emyria Limited engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia. It develops MDMA-inspired medicines, including EMD-MX1, for faster-acting MDMA with improved side-effect profile for drug-assisted therapies; EMD-MX2, an adjunct for Parkinson’s disease to improve side effects of a common treatment; and EMD-MX3 for other neurological indications. The company is also developing EMD-RX7/9, a CBD capsule prescription medicines for complex pain and anxiety which is ...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: EMD

Financial Performance

In 2024, Emyria's revenue was 2.20 million, an increase of 38.32% compared to the previous year's 1.59 million. Losses were -11.46 million, 123.3% more than in 2023.